Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7981079 | 0.81 | PTGS1 (0.67) | PTGS1PTGS2LMNACYP1A2KMT2A | |
| SCHEMBL6739461 | 0.80 | PTGS1 (0.61) | PTGS1PTGS2LMNACYP1A2KMT2A | |
| SCHEMBL3685087 | 0.76 | PTGS1 (0.61) | PTGS1PTGS2LMNACYP1A2KMT2A | |
| SCHEMBL29174927 | 0.76 | PTGS1 (0.61) | PTGS1PTGS2LMNACYP1A2KMT2A | |
| SCHEMBL6491847 | 0.76 | KDM4E (0.49) | PTGS1PTGS2KMT2AMEN1GAA | |
| SCHEMBL31040146 | 0.74 | PTGS1 (1.00) | PTGS1PTGS2LMNACYP1A2KMT2A | |
| SCHEMBL11539578 | 0.74 | PTGS1 (0.62) | PTGS1PTGS2LMNACYP1A2KMT2A | |
| SCHEMBL13144236 | 0.74 | KDM4E (0.50) | PTGS1PTGS2KMT2AMEN1GAA | |
| SCHEMBL6491851 | 0.74 | KDM4E (0.50) | CYP1A2KMT2AMEN1GAAALDH1A1 | |
| SCHEMBL31040215 | 0.72 | PTGS1 (0.64) | PTGS1PTGS2LMNACYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | PTGS1 2300/4885PTGS2 2931/4885LMNA 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.